BioCryst Pharmaceuticals Q4 Loss Shrinks 51% on Higher Collaborative Revenue

BioCryst Pharmaceuticals reports a big jump in revenue amid tame expense growth, but investors will want to note the company's current cash balance and expected burn rate for 2014.

Feb 26, 2014 at 12:15PM

Following yesterday's double-digit gains after the Food and Drug Administration accepted its new drug application (NDA) filing for peramivir as a treatment for influenza, BioCryst Pharmaceuticals (NASDAQ:BCRX) hoped to keep the good times rolling with the release of its fourth-quarter earnings results before the opening bell this morning.

For the quarter, BioCryst reported a 158% spike higher in revenue to $10.05 million from $4.1 million, which was primarily tied to collaborative revenue from its contract with the Biomedical Advanced Research and Development Authority, and Department of Health and Human Services. Revenue recognition from this contract was mostly associated with its December 2013 NDA filing for peramivir. BioCryst also delivered a 12% increase in royalty revenue to $0.52 million.

Thanks to this higher revenue recognition and relatively tame cost expansion BioCryst was able to reduce its quarterly net loss by more than half to $5.43 million, or $0.09 per share, from $11.05 million, or $0.22 per share.

Total operating expenses rose $2.11 million, or 14%, primarily because research and development costs jumped $4.52 million. BioCryst attributed these higher R&D costs to peramivir and its ongoing hereditary angioedema drug development program. However, BioCryst recognized no restructuring costs compared to $1.76 million during the fourth quarter of 2012, and saw general and administrative expenses decline by 34% to $1.27 million.

Looking ahead, BioCryst anticipates net cash usage will equal $35 million to $43 million in fiscal 2014, including operating expenses in the range of $48 million to $59 million. This is worth keeping an eye on as BioCryst ended the fourth quarter with just $40.8 million in cash and cash equivalents. The company also notes that because of the way it recognizes revenue and develops therapies per its contracts, revenue is expected to fall year-over-year in 2014. 

link

Sean Williams has no material interest in any companies mentioned in this article. You can follow him on CAPS under the screen name TMFUltraLong, track every pick he makes under the screen name TrackUltraLong, and check him out on Twitter, where he goes by the handle @TMFUltraLong.

The Motley Fool has no position in any companies mentioned in this article. Try any of our Foolish newsletter services free for 30 days. We Fools don't all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.

1 Key Step to Get Rich

Our mission at The Motley Fool is to help the world invest better. Whether that’s helping people overcome their fear of stocks all the way to offering clear and successful guidance on complicated-sounding options trades, we can help.

Feb 1, 2016 at 4:54PM

To be perfectly clear, this is not a get-rich action that my Foolish colleagues and I came up with. But we wouldn't argue with the approach.

A 2015 Business Insider article titled, "11 websites to bookmark if you want to get rich" rated The Motley Fool as the #1 place online to get smarter about investing.

"The Motley Fool aims to build a strong investment community, which it does by providing a variety of resources: the website, books, a newspaper column, a radio [show], and [newsletters]," wrote (the clearly insightful and talented) money reporter Kathleen Elkins. "This site has something for every type of investor, from basic lessons for beginners to investing commentary on mutual funds, stock sectors, and value for the more advanced."

Our mission at The Motley Fool is to help the world invest better, so it's nice to receive that kind of recognition. It lets us know we're doing our job.

Whether that's helping the entirely uninitiated overcome their fear of stocks all the way to offering clear and successful guidance on complicated-sounding options trades, we want to provide our readers with a boost to the next step on their journey to financial independence.

Articles and beyond

As Business Insider wrote, there are a number of resources available from the Fool for investors of all levels and styles.

In addition to the dozens of free articles we publish every day on our website, I want to highlight two must-see spots in your tour of fool.com.

For the beginning investor

Investing can seem like a Big Deal to those who have yet to buy their first stock. Many investment professionals try to infuse the conversation with jargon in order to deter individual investors from tackling it on their own (and to justify their often sky-high fees).

But the individual investor can beat the market. The real secret to investing is that it doesn't take tons of money, endless hours, or super-secret formulas that only experts possess.

That's why we created a best-selling guide that walks investors-to-be through everything they need to know to get started. And because we're so dedicated to our mission, we've made that available for free.

If you're just starting out (or want to help out someone who is), go to www.fool.com/beginners, drop in your email address, and you'll be able to instantly access the quick-read guide ... for free.

For the listener

Whether it's on the stationary exercise bike or during my daily commute, I spend a lot of time going nowhere. But I've found a way to make that time benefit me.

The Motley Fool offers five podcasts that I refer to as "binge-worthy financial information."

Motley Fool Money features a team of our analysts discussing the week's top business and investing stories, interviews, and an inside look at the stocks on our radar. It's also featured on several dozen radio stations across the country.

The hosts of Motley Fool Answers challenge the conventional wisdom on life's biggest financial issues to reveal what you really need to know to make smart money moves.

David Gardner, co-founder of The Motley Fool, is among the most respected and trusted sources on investing. And he's the host of Rule Breaker Investing, in which he shares his insights into today's most innovative and disruptive companies ... and how to profit from them.

Market Foolery is our daily look at stocks in the news, as well as the top business and investing stories.

And Industry Focus offers a deeper dive into a specific industry and the stories making headlines. Healthcare, technology, energy, consumer goods, and other industries take turns in the spotlight.

They're all informative, entertaining, and eminently listenable ... and I don't say that simply because the hosts all sit within a Nerf-gun shot of my desk. Rule Breaker Investing and Answers contain timeless advice, so you might want to go back to the beginning with those. The other three take their cues from the market, so you'll want to listen to the most recent first. All are available at www.fool.com/podcasts.

But wait, there's more

The book and the podcasts – both free ... both awesome – also come with an ongoing benefit. If you download the book, or if you enter your email address in the magical box at the podcasts page, you'll get ongoing market coverage sent straight to your inbox.

Investor Insights is valuable and enjoyable coverage of everything from macroeconomic events to investing strategies to our analyst's travels around the world to find the next big thing. Also free.

Get the book. Listen to a podcast. Sign up for Investor Insights. I'm not saying that any of those things will make you rich ... but Business Insider seems to think so.


Compare Brokers